

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of this fund. You are advised to read it so you can make an informed decision about whether to invest.

## FCP MEDICAL BioHealth-Trends EUR

FCP MEDICAL BioHealthTrends

ISIN LU0119891520

Managed by Hauck & Aufhäuser Fund Services S.A. (HAFS). HAFS belongs to the Hauck & Aufhäuser Group.

### Objectives & Investment Policy

The aim of FCP MEDICAL BioHealth-Trends EUR is to achieve an attractive increase in value in euros. At least two thirds is invested in the share classifications of biotechnology, medical technology, health and pharmaceuticals. A global choice of titles can be considered whereby most companies from the stipulated industries are located in the US. The fund will bear the fees for the purchase and sale of securities. They are incurred in addition to the percentages listed under 'Charges' and may reduce the fund's profits. The fund's yields are always distributed. The investors can request the withdrawal of their shares from the management

company whenever the stock market is open. The management company can however stop withdrawal if extraordinary circumstances make this appear necessary when taking the investor's interests into account. The fund is suitable for experienced investors who want to take advantage of above-average chances of growth and are willing to accept stronger capital variations for a time as well as potentially significant losses. The fund should be used as a long-term strategic combination of industries within a range of security assets. As a result of its special investment policy the fund has a stronger opportunity-risk profile.

### Risk and Reward Profile



Historical data may not be a reliable indication for the future. The risk category shown is not guaranteed and may shift over time. Even the lowest category does not mean 'risk free'. The fund has been categorized SRRI 6 because its net asset value shows heavy volatility leading to high probabilities for losses as well as gains. Risks that could significantly affect fund performance and are not necessarily fully reflected in the risk and reward rating include: Since the fund has a special focus on the health care sector the risk profile of the fund is higher than the risk profile of a fund that has no special sector concentration.

# FCP MEDICAL BioHealth-Trends EUR

FCP MEDICAL BioHealthTrends

## Charges for this fund

The charges you pay are used to pay the costs of running the fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest.

**Entry charge** 5,00%

**Exit charge** 0,00%

Charges taken from the fund over a year

**Ongoing charges** 2,23%

Charges taken from the fund under certain specific conditions


**Performance fee** 0,63%

The issue and withdrawal fees shown are maximum values. It is the maximum amount that can be deducted from your investment amount. In some cases the amount you pay may be lower - your financial advisor will be able to provide this information to you. The value for the ongoing charges is based on the expenses for the completed financial year. This value may vary from year to year. The ongoing charges do not include the performance-dependent fee or transaction charges. Performance fees about 3,12 % were charged during the last financial year.

Performance-dependent fee related to the fund's value development that exceeds 2.5% every six months. This premium is only paid if the net inventory value per share at the end of the six months - compared with the highest level at the end of the former six months - has reached a new high level (the 'high water

mark') and only on the new increase in value above this that exceeds the stated highest level of the net inventory value per share at the end of the previous six months. The sales brochure will provide details.

## Past Performance



Past performance is no guarantee for future performance. All charges and fees with the exception of the issue supplement were deducted for the calculation. FCP MEDICAL BioHealth-Trends EUR was established in 2000. The historical value development was calculated in euros.

## Practical Information

- Hauck & Aufhäuser Fund Platforms S.A. is the depository for this fund.
- The sales brochure, current reports, current share prices and additional information on the fund is found free of charge in German at our website [www.hauck-aufhaeuser.com](http://www.hauck-aufhaeuser.com)
- This fund is subject to the laws and tax regulations of Luxembourg. This may affect for example how your income from the fund is taxed.
- FCP MEDICAL BioHealthTrends is an undertaking for collective investment subject to Part I of the Law of 17 December 2010 and is as such subject to the prudential supervision of the Commission de Surveillance du Secteur Financier ("CSSF"). According to Article 2 of the Law of 23 December 1998 the CSSF is the competent authority responsible for the prudential supervision of undertakings for collective undertakings.
- Hauck & Aufhäuser Fund Services S.A. may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the fund.
- Details of the current remuneration policy, including a description of how remuneration and other benefits are calculated, and the identity of those responsible for allocating remuneration and other benefits, including the composition of the remuneration committee (if such a committee exists) are available on the Management Company's website at (<https://www.hauck-aufhaeuser.com/en/rechtliche-hinweise/legal-notice>). In addition, a paper version is available on request free of charge from the Management Company.
- There are other classes of this fund available.

This fund is authorised in Luxembourg and regulated by Commission de Surveillance du Secteur Financier (CSSF).

This key investor information is accurate as at 15.06.2018.